Know Cancer

forgot password

A Phase I/II Multi-Dose Study of SGN-30 in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Phase 1/Phase 2
18 Years
Not Enrolling
Hodgkin Disease, Lymphoma, Large-Cell, Sarcoma, Kaposi, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell

Thank you

Trial Information

A Phase I/II Multi-Dose Study of SGN-30 in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Inclusion Criteria


Histologically confirmed CD30+ hematologic malignancy. Immunohistochemistry or flow
cytometry may be performed on either original diagnostic biopsy material or biopsy of
relapsed disease.

Patients must have at least one of the following:

- Patients with HD must have failed systemic chemotherapy either as initial therapy for
advanced stage disease or as salvage therapy after initial radiotherapy (XRT) for
early stage disease and be ineligible for, or refuse treatment by stem cell

- Patients with other CD30+ malignancies must be beyond 1st remission or refractory to
front line chemotherapy

- Patients with refractory or chemo-resistant multiple myeloma (MM), as defined by a
failure to respond (<50% reduction in M-protein level), or disease progression less
than 2 months after receiving at least two conventional chemotherapy regimens

- Patients with MM in the Plateau Phase of their disease may be included in the study.
Plateau phase will be defined as persistent (more than 6 weeks) M-protein in the
serum or urine despite a significant initial reduction (>50%) in response to previous
therapy. These patients should have received at least two of the conventional
chemotherapy regimens listed above prior to enrollment in this study.

- Patients with relapsed MM as defined by disease progression more than 2 months after
initial therapy and subsequent failure to respond (<50% reduction or progression in
M-protein levels) to ONE of the above listed regimens or other salvage regimens (high
dose cyclophosphamide, topotecan).

Patients must have at least one of the following:

- Bidimensional or unidimensional measurable disease on physical examination or
radiologic evaluation

- Circulating tumor cells in peripheral blood

- Evidence of bone marrow disease to any degree in patients with HD

- >10% tumor cells in bone marrow in patients with other CD30+ malignancies

- Minimum of 4 weeks from last therapy (including radiotherapy or chemotherapy); a
minimum of 6 weeks from last treatment with nitrogen mustard agents, melphalan or

- ECOG performance status ≤ 2 (Appendix B) with a life expectancy > 3 months


- A diagnosis of Cutaneous T-Cell Lymphoma (CTCL) or non-secretory MM

- Symptomatic cardiac disease including ventricular dysfunction, coronary artery
disease or arrhythmias

- More than one primary malignancy with the exception of non-melanoma skin cancer or
cervical carcinoma in situ (CIN) on a biopsy or squamous intraepithelial lesion (SIL)
on PAP smear

- Active viral, bacterial, or systemic fungal infection including known HIV positivity

- Symptomatic brain metastases requiring treatment

- Concurrent therapy with other anti-neoplastic agents, corticosteroids, or
experimental agents

- Any serious underlying medical condition which would impair the ability of the
patient to receive or tolerate the planned treatment including prior allergic
reactions to recombinant human or murine proteins

- Receipt of any therapeutic mAbs within 6 months unless a recent serum testing reveals
no antibody titer and no evidence of anti-chimeric or anti-murine antibody in the
peripheral circulation

- Female patients who are pregnant or breastfeeding

- Dementia or altered mental status that would prohibit the understanding and rendering
of informed consent

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Amy P Sing, MD

Investigator Role:

Study Director

Investigator Affiliation:

Seattle Genetics, Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

Completion Date:

August 2003

Related Keywords:

  • Hodgkin Disease
  • Lymphoma, Large-Cell
  • Sarcoma, Kaposi
  • Lymphoma, T-Cell, Cutaneous
  • Lymphoma, B-Cell
  • Hodgkin Disease
  • Lymphoma
  • Sarcoma, Kaposi
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • Lymphoma, T-Cell
  • Lymphoma, T-Cell, Cutaneous
  • Hematologic Neoplasms
  • Sarcoma



MD Anderson Cancer Center Houston, Texas  77030-4096
Siteman Cancer Center Saint Louis, Missouri  63110
University of Washington Seattle, Washington  98195
University of Rochester Rochester, New York  14642
Dana Farber Cancer Institute Boston, Massachusetts  02115
University of Miami Miami, Florida  33136
University of Alabama, Birmingham Birmingham, Alabama  35233
USC Norris Cancer Center Los Angeles, California  90033
University of Nebraska Omaha, Nebraska  68198
Cornell Medical College, New York Presbyterian New York, New York  10021